** Shares of drug developer Vigil Neuroscience VIGL.O rise 10% to $2.25
** VIGL says its experimental Alzheimer's drug, VG-3927, reduced key biomarker sTREM2 by up to 50% in cerebral spinal fluid in early-stage trial
** Reduction in sTREM2 levels is expected to help slow progression of Alzheimer's disease, as higher levels suggest brain inflammation
** Co says VG-3927 was well-tolerated and has favorable pharmacokinetic and pharmacodynamic profile in the trial
** VIGL plans to advance into mid-stage trial in Q3 2025
** 8 of 9 brokerages rate stock "buy" or higher and 1 "sell"; their median PT is $16.50 - data compiled by LSEG
** VIGL fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。